{'52WeekChange': -0.047658145,
 'SandP52WeekChange': None,
 'address1': '440, Boulevard Armand-Frappier',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.3,
 'askSize': 3000,
 'averageDailyVolume10Day': 71750,
 'averageVolume': 66939,
 'averageVolume10days': 71750,
 'beta': 1.58013,
 'beta3Year': None,
 'bid': 10.5,
 'bidSize': 1200,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Laval',
 'companyOfficers': [],
 'country': 'Canada',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 11.39,
 'dayLow': 10.79,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 264415776,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '450-781-4477',
 'fiftyDayAverage': 11.826049,
 'fiftyTwoWeekHigh': 31.45,
 'fiftyTwoWeekLow': 5.25,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 3550525,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 300,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.71387,
 'heldPercentInstitutions': 0.14226,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1562284800,
 'lastSplitFactor': '1:1000',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/liminalbiosciences.com',
 'longBusinessSummary': 'Liminal BioSciences Inc. operates as a '
                        'biopharmaceutical company with two drug discovery '
                        'platforms that focuses on unmet medical needs. It '
                        'operates through three segments: Small Molecule '
                        'Therapeutics, Plasma Derived Therapeutics, and '
                        'Bioseparations. The Small Molecule Therapeutics '
                        "segment's lead product candidate is PBI-4050, which "
                        'targets unmet medical needs, such as the treatment of '
                        'idiopathic pulmonary fibrosis, Alstr√∂m syndrome, and '
                        'other fibrotic indications. The Plasma Derived '
                        'Therapeutics segment provides Plasma Protein '
                        'Purification System, a multi-product sequential '
                        'purification process for the extraction and '
                        'purification of therapeutic proteins from human '
                        'plasma. It also engages in developing Ryplazim for '
                        'the treatment of congenital plasminogen deficiency. '
                        'The Bioseparations segment develops and manufactures '
                        'affinity absorbents and Mimetic Ligand purification '
                        'platform that are used by pharmaceutical and medical '
                        'companies for extraction and purification '
                        'manufacturing processes. In addition, it develops '
                        'processes to recover and purify various other '
                        'proteins from plasma, including intravenous '
                        'immunoglobulin, inter-alpha-inhibitor-proteins, '
                        'fibrinogen, alpha1 antitrypsin, and C1 esterase '
                        'inhibitor. Liminal BioSciences has partnership with '
                        'CoVIg plasma alliance for the development of COVID-19 '
                        'therapy. The company was formerly known as Prometic '
                        'Life Sciences Inc. and changed its name to Liminal '
                        'BioSciences Inc. in October 2019. Liminal BioSciences '
                        'Inc. was incorporated in 1994 and is headquartered in '
                        'Laval, Canada.',
 'longName': 'Liminal BioSciences Inc.',
 'market': 'us_market',
 'marketCap': 254142448,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_882426',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 11.24,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '450-781-0115',
 'previousClose': 11.59,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 11.39,
 'regularMarketDayLow': 10.79,
 'regularMarketOpen': 11.24,
 'regularMarketPreviousClose': 11.59,
 'regularMarketPrice': 11.24,
 'regularMarketVolume': 19834,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 23622700,
 'sharesPercentSharesOut': 0.0016,
 'sharesShort': 38445,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 35995,
 'shortName': 'Liminal BioSciences Inc.',
 'shortPercentOfFloat': 0.0114,
 'shortRatio': 2.06,
 'startDate': None,
 'state': 'QC',
 'strikePrice': None,
 'symbol': 'LMNL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 9.495891,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'f236eeeb-67d8-3cc6-a9dd-5516ebc191a0',
 'volume': 19834,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.liminalbiosciences.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'H7V 4B4'}